Hetriva Rivastigmine Transdermal Patch for Dementia & Alzheimer’s

What is Hetriva?

Hetriva is a Rivastigmine transdermal patch designed to support cognitive function in people experiencing dementia due to Alzheimer’s or Parkinson’s disease. It ensures controlled, continuous delivery of medication, making it easier for the brain to maintain healthy communication between nerve cells.

How Hetriva Works

• Rivastigmine increases levels of acetylcholine, a neurotransmitter essential for memory and cognition.
• The patch stays active for 24 hours, providing steady absorption without spikes or crashes.
• Transdermal delivery improves tolerability, especially in elderly patients or those with digestive issues.
• Regular use may help improve memory, attention, responsiveness, and daily activity performance.

Why Choose Hetriva?

• Gentle, continuous Rivastigmine delivery
• Fewer stomach-related side effects than oral tablets
• Improves medication adherence
• Ideal for elderly patients or those with swallowing difficulties
• Clinically proven for Alzheimer’s and Parkinson’s dementia
• Supports cognitive function and slows symptom progression

Who Is Hetriva For?

Hetriva is recommended for individuals diagnosed with:

• Mild to Moderate Alzheimer’s Disease
• Dementia associated with Parkinson’s Disease
• Cognitive decline affecting memory, attention, and daily functioning

How To Apply

• Apply once daily to clean, dry, hairless skin (upper arm, chest, upper back, lower back). =
• Press firmly for 10–15 seconds.
• Avoid applying heat over the patch.
• Rotate application areas daily to avoid irritation.

Dosage & Administration

The typical dosage is as follows:

• Initiate: 9 mg patch
• Maintenance: 18 mg patch (after 4 weeks)
• Continue: 27 mg patch (after 4 weeks)

Benefits

• Supports memory and daily functioning
• Improves thinking and attention
• Reduces confusion and behavioral changes
• Fewer side effects than oral pills
• Easy once-daily use
• Continuous delivery for steady cognitive support

Side Effects (Mild & Common)

• Skin redness or itching
• Nausea or reduced appetite
• Headache or dizziness
• Mild weight loss
• Sleep disturbances

Most effects are temporary and improve with consistent use and rotation of patch sites.

Caution & Safety

Consult a doctor before use if the patient has:

• Severe heart disease
• Stomach ulcers
• Liver/kidney impairment
• Breathing disorders (asthma/COPD)
• Known skin allergies

Conclusion

Hetriva Rivastigmine Patch offers a reliable, caregiver-friendly solution to support memory, thinking, and daily functioning in patients with Alzheimer’s or Parkinson’s dementia. Its transdermal delivery ensures comfort, stability, and improved adherence — helping patients maintain cognitive ability and quality of life for as long as possible.

Product Overview:

The Hetriva Transdermal Patch is a brand of Rivastigmine, a medicine used to treat dementia.

Composition: Each patch contains Rivastigmine in dosages of 9, 18, and 27 mg.

Mechanism of Action:

• Dual inhibition: Rivastigmine blocks both acetylcholinesterase and butyrylcholinesterase, boosting acetylcholine levels in the brain and improving cognitive function.

Pharmacokinetics:

• Bioavailability: About 60-72% of the medicine is absorbed into the body.
• Metabolism: The medicine is processed by the liver.
• Elimination: The body gets rid of the medicine in about 2 hours, and 97% of it is excreted in urine.

Dosing & Administration:

The Hetriva patch is prescribed in a step-up or "titration" process:

• Start: Use the 9 mg patch to begin treatment.
• Maintenance: After 4 weeks, the dosage is increased to the 18 mg patch.
• Continue: After another 4 weeks, the dosage can be increased to the 27 mg patch.

Note: For severe GI side effects or if treatment is missed >3 days, pause or restart with the 9 mg patch.

Switching from Oral to Patch

• For patients on low oral dose (< 6 mg/day):Switch directly to 9 mg patch.
• For patients on higher oral dose (6–12 mg/day): Switch directly to 18 mg patch.

Contraindications:

• Hypersensitivity: History of reaction to carbamate derivatives
• Skin reactions: History of allergic dermatitis to patches
• Hepatic/Renal impairment: Use with caution in severe cases
• Pregnancy: Use only if potential benefit outweighs risk
• Breastfeeding: Use only if potential benefit outweighs risk
• Cardiac conduction abnormalities: Monitor closely

Drug Interactions:

• Avoid concomitant use with other cholinesterase inhibitors
• Use caution with drugs like digoxin, diazepam, warfarin, or fluoxetine due to potential interactions.

Clinical Evidence

• RCTs confirm improved cognition and daily functioning in Alzheimer’s and Parkinson’s dementia.
• Patch shows ~30–40% fewer GI side effects compared to oral rivastigmine.
• Demonstrates higher adherence (>70%) versus oral formulations (~50%).
• Well-tolerated with sustained efficacy in long-term therapy.

Storage & Handling

• Storage: Store at 20–25°C in a dry place.
• Dispose of used patches responsibly
• Keep sealed until use to prevent drug loss

Patient Suitability

• Mild to moderate Alzheimer’s or Parkinson’s dementia.
• Patients unable to swallow pills.
• Those needing steady once-daily therapy with better GI tolerance.

Supporting Tools & Resources

• Patient Guides: Patch application & titration instructions
• Monitoring Charts: Track cognition & daily function
• Clinic Posters: Reinforce adherence & caregiver education
• Mantra Bot: Smart reminders & adherence tracking for your patients